Skip to main content

Table 1 Experience with biologics in juvenile dermatomyositis in survey #1 in 2012

From: Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America

No experience at all 35 (39%)
Etanercept 5 (5%)
Abatacept 0 (0.0%)
Adalimumab 0 (0.0%)
Infliximab 4 (4%)
Anakinra 1 (1%)
Tocilizumab 0 (0.0%)
Rituximab 29 (32%)
Canakinumab 0 (0%)
Multiple 16 (18%)
Other 1 (1%)